<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538134</url>
  </required_header>
  <id_info>
    <org_study_id>MHST2012-01B</org_study_id>
    <nct_id>NCT01538134</nct_id>
  </id_info>
  <brief_title>Antiphospholipid Antibodies and Fetal Growth Restriction</brief_title>
  <official_title>Antiphospholipid Antibodies and Early Fetal Growth Restriction (&lt;34 Weeks of Gestation). A Case Control Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Thomas Hospital, Panama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Thomas Hospital, Panama</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed
      against cell membrane phospholipids (antiphospholipid antibodies) can cause an
      hypercoagulable state that causes thrombosis and obstetric complications (miscarriages,
      stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis
      includes the development of fetal growth restriction (diagnosed postpartum), but this was
      done without solid evidence of a relation between the two or using the most common form of
      fetal growth restriction diagnosis (ultrasound). Our study will try to add information to
      this particular point.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lupus anticoagulant</measure>
    <time_frame>8 months</time_frame>
    <description>Number of cases positive for Lupus Anticoagulant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anticardiolipin antibodies</measure>
    <time_frame>10 months</time_frame>
    <description>Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B2 Glycoprotein I</measure>
    <time_frame>10 months</time_frame>
    <description>Number of cases with levels of B2 Glycoprotein I &gt; 99%</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Fetal Growth Restriction</condition>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients with ultrasonographic diagnosis of fetal growth restriction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with normal pregnancies at term.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant patients admitted for fetal growth restriction (cases) and normal patients in
        labor at term (controls).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age between 24-34 weeks.

          -  Ultrasonographic evidence of fetal growth restriction

               -  Abdominal circumference &lt; 3rd percentile.

               -  Doppler with increase of placental resistance.

        Exclusion Criteria:

          -  Known antiphospholipid syndrome.

          -  Known presence of antiphospholipid antibodies.

          -  Patients with systemic lupus erythematosus.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osvaldo Reyes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Thomas Hospital, Panama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Thomas Maternity Hospital</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>January 1, 2015</last_update_submitted>
  <last_update_submitted_qc>January 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Thomas Hospital, Panama</investigator_affiliation>
    <investigator_full_name>Osvaldo A. Reyes T.</investigator_full_name>
    <investigator_title>Coordinator of Research &amp; Development</investigator_title>
  </responsible_party>
  <keyword>Antibodies, anticardiolipin</keyword>
  <keyword>Antibodies, B2 Glycoprotein I</keyword>
  <keyword>Lupus Anticoagulant</keyword>
  <keyword>Fetal Growth Restriction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Antiphospholipid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

